IMC-EB10 treatment still reduces leukemic engraftment and prolongs the survival of NOD/SCID mice injected with FLT3 TKI-sensitive or -resistant cell lines. (A) NOD/SCID mice, in groups of 5, were injected with 0.5 × 106 SEM-K2, SEM(R)5214, or SEM(R)701 cells via tail-vein injection. Starting 24 hours after cell injection, mice were injected intraperitoneally a total of 3 times with 400 μg IMC-C225 or IMC-EB10, given every other day. Mice were killed 30 days after cell injection, and bone marrow cells were obtained from femurs. Cells harvested from femurs were stained with hCD19-FITC, mCD45-PE, and hCD45-APC, and human engraftment was determined by flow cytometry. (B) NOD/SCID mice, in groups of 10, were injected with 0.5 × 106 Molm14, M14(R)5214, or M14(R)701 cells via tail-vein injection. Starting 24 hours after cell injection, mice were injected intraperitoneally a total of 3 times with 400 μg IMC-C225 or IMC-EB10, given every other day. Mice were monitored daily for survival.
